STOCK TITAN

Cogent Biosciences, Inc. - $COGT STOCK NEWS

Welcome to our dedicated page for Cogent Biosciences news (Ticker: $COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cogent Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cogent Biosciences's position in the market.

Rhea-AI Summary
Cogent Biosciences, Inc. (Nasdaq: COGT) will review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) and provide an additional clinical data update from APEX Part 1 in patients with Advanced Systemic Mastocytosis (AdvSM). The investor webcast will be held on Monday, December 11, 2023, at 8:00 a.m. ET. The SUMMIT data will be presented at the American Society of Hematology (ASH) Annual Meeting on December 9, 2023, and the APEX data will be presented in a poster session on December 11, 2023. The webcast will feature presentations by Cogent's President and CEO, Andrew Robbins, as well as leading medical professionals. The live webcast and replay will be accessible on Cogent's website at investors.cogentbio.com/events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
conferences clinical trial
-
Rhea-AI Summary
Cogent Biosciences, Inc. (Nasdaq: COGT) announced two poster presentations at the 2023 San Antonio Breast Cancer Symposium, showcasing their precision therapies for genetically defined diseases. The posters will feature a brain penetrant, EGFR sparing, ErbB2 inhibitor and a wild-type-sparing, PI3Kα H1047R mutant-selective inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.67%
Tags
none
-
Rhea-AI Summary
Cogent Biosciences, Inc. reported recent business highlights and financial results for Q3 2023. They completed enrollment for SUMMIT Part 1 and expect to begin SUMMIT Part 2 in 1H 2024. Updated PEAK lead-in data showed a 33% ORR and over 14 months median duration of treatment for 2nd-line GIST patients. The company ended Q3 with $312.8 million cash, providing runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
Rhea-AI Summary
Cogent Biosciences, Inc. reported financial results for Q2 2023, ending with $350.9 million in cash. Positive data from Phase 3 PEAK trial on bezuclastinib and sunitinib combination in GIST patients. Selective FGFR2 inhibitor nominated as first clinical candidate. Preclinical data on ErbB2 inhibitor presented. Completed public offering with net proceeds of approximately $161.8 million. Upcoming milestones include presenting clinical data from SUMMIT and APEX trials in 2H 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.21%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.21%
Tags
-
Cogent Biosciences, Inc.

Nasdaq:COGT

COGT Rankings

COGT Stock Data

719.97M
80.04M
0.14%
100.15%
11.34%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WALTHAM

About COGT

unum therapeutics is a cambridge, massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. unum has built an antibody-coupled t-cell receptor (actr) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic t-lymphocytes (ctls) to kill tumor cells. in contrast to other approaches that hit a single target and treat a narrow set of tumors, unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. unum’s vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. unum's lead program based on actr technology is currently in phase i clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. in parallel, unum is act